These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 8996737

  • 21. In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.
    Holt HA, Bywater MJ, Reeves DS.
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():7-12. PubMed ID: 2292533
    [Abstract] [Full Text] [Related]

  • 22. [Comparative study of the antibacterial activity of cefpodoxime against enterobacteria producing beta lactamases].
    Siebor E, Cordin X, Delpech N, Duez JM, Kazmierczak A.
    Pathol Biol (Paris); 1990 May; 38(5):331-5. PubMed ID: 2367149
    [Abstract] [Full Text] [Related]

  • 23. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T, Otsuki M, Hatano K, Nishihara Y.
    Chemotherapy; 1994 May; 40(3):167-82. PubMed ID: 8205935
    [Abstract] [Full Text] [Related]

  • 24. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K, Koyama H, Chiba A, Omika K, Harada S, Sato Y, Hasegawa M, Kobayashi I, Kaneko A, Sasaki J.
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.
    Sarubbi FA, Verghese A, Caggiano C, Holtsclaw-Berk S, Berk SL.
    Antimicrob Agents Chemother; 1989 Jan; 33(1):113-4. PubMed ID: 2496654
    [Abstract] [Full Text] [Related]

  • 26. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS.
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [Abstract] [Full Text] [Related]

  • 27. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
    Bauernfeind A.
    Diagn Microbiol Infect Dis; 1991 May; 14(1):63-74. PubMed ID: 2013211
    [Abstract] [Full Text] [Related]

  • 28. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C, Milatovic D, Braveny I.
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS, Flamm RK, Jones RN.
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [Abstract] [Full Text] [Related]

  • 32. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, Tympanidou C, Giamarellou H.
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [Abstract] [Full Text] [Related]

  • 33. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B, Luhmer E, Zühlsdorf MT.
    Drugs; 1991 Mar; 42 Suppl 3():6-12. PubMed ID: 1726210
    [Abstract] [Full Text] [Related]

  • 34. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
    Westblom TU, Gudipati S, Midkiff BR.
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):691-3. PubMed ID: 2226500
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].
    Dubreuil L, Derriennic M, Sedallian A.
    Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150
    [Abstract] [Full Text] [Related]

  • 37. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN.
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy CJ.
    Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
    [Abstract] [Full Text] [Related]

  • 40. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS, Karavokiros KT, Taeubel MA, Itokazu GS.
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.